Medicure (TSXV:MPH) Moat Score: 2/10 (As of Jul. 12, 2026)


TSXV:MPH Medicure Inc TSXV:MPH
52 GF Score
Price C$1.06
GF Value C$1.56
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicure Moat Score?

Medicure TSXV:MPH 52 Moat Score is 2 as of Jul. 12, 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 52/100 and a GF Value™ of C$1.56 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Medicure ranks better than 81.57% on this metric.

Medicure has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Medicure has No Moat: Medicure Inc lacks significant market leadership, customer switching costs, and brand strength. The company does not have durable cost advantages or significant regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medicure might have No Moat - Very weak/transient advantages.

Medicure  (TSXV:MPH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medicure Moat Score Related Terms

TSXV:MPH vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicure Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's Moat Score distribution charts can be found below:

* The bar in red indicates where Medicure's Moat Score falls into.


TSXV:MPH
52GF Score
Medicure Inc TSXV:MPH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Medicure (TSXV:MPH) has a Moat Score of 2 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Medicure ranks #190 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.4%.
Is Medicure's Moat Score too high?
Medicure's current Moat Score is 2. Based on the distribution chart, Medicure ranks #190 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medicure has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicure's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #190 out of 1031 companies for Moat Score. This places Medicure in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Medicure's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Possible Value Trap. The stock's GF Value™ is C$1.56, compared to a current price of C$1.06 — trading 32.1% below its estimated fair value. The current Moat Score is 2. Medicure's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Moat Score is 2 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicure (TSXV:MPH) Overvalued in 2026?

Based on GuruFocus' analysis, Medicure stock appears to be undervalued. The current stock price of C$1.06 is trading 32.1% below its estimated GF Value™ of C$1.56. GuruFocus considers Medicure to be Possible Value Trap.

Key valuation signals for TSXV:MPH:

  • Moat Score: 2
  • GF Value™: C$1.56 vs. price of C$1.06 (32.1% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicure Business Description

Other Exchanges MCUJF:USA
Address 1250 Waverley Street, No. 2, Winnipeg, MB, CAN, R3T 6C6
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
52GF Score

Get the complete analysis for TSXV:MPH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.06
Price
C$1.56
GF Value